Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous BM-MSC for Relapsing-Remitting Multiple Sclerosis
NCT02035514Phase 2Completed
- Sponsor
- Hospital Universitari Germans Trias i Pujol
- Start
- Dec 2013
- Primary completion
- Jul 2016
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous bone marrow derived mesenchymal stromal cells in relapsing-remitting multiple sclerosis (RRMS), sponsored by Hospital Universitari Germans Trias i Pujol. Started Dec 2013; status: completed.
02
Drugs
autologous bone marrow derived mesenchymal stromal cells
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT02035514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02035514.